Patents by Inventor Samuel Broder
Samuel Broder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9474793Abstract: The present invention provides methods for lowering a viral load of a virus resistant to an antiviral drug by inducing cytotoxic T lymphocytes (CTL) to recognize a predetermined mutated epitope within a viral protein of the drug-resistant virus. CTLs are induced by immunizing a host with a peptide comprising the predetermined mutation. The immunostimulating peptide may be further improved by epitope-enhancement for inducing specific CTLs. The antiviral protection against drug-resistant virus shown by compositions of the present invention and mediated by human HLA-restricted CTL has not been previously achieved.Type: GrantFiled: February 22, 2006Date of Patent: October 25, 2016Assignee: The United States of America, as represented by the Secretary of the Department of Health and Human ServicesInventors: Andrew Catanzaro, Robert Yarchoan, Jay A. Berzofsky, Takahiro Okazaki, James T. Snyder, II, Samuel Broder
-
Publication number: 20090317418Abstract: The present invention provides methods for lowering a viral load of a virus resistant to an antiviral drug by inducing cytotoxic T lymphocytes (CTL) to recognize a predetermined mutated epitope within a viral protein of the drug-resistant virus. CTLs are induced by immunizing a host with a peptide comprising the predetermined mutation. The immunostimulating peptide may be further improved by epitope-enhancement for inducing specific CTLs. The antiviral protection against drug-resistant virus shown by compositions of the present invention and mediated by human HLA-restricted CTL has not been previously achieved.Type: ApplicationFiled: February 22, 2006Publication date: December 24, 2009Applicant: THE GOV'T OF USOA as represented by the SECRETARY OF THE DEPT OF HHSInventors: Andrew Catanzaro, Robert Yarchoan, Jay A. Berzofsky, Takahiro Okazaki, James T. Snyder, II, Samuel Broder
-
Publication number: 20070060635Abstract: A method of increasing the bioavailability upon oral administration of a pharmacologically active target agent, particularly an antitumor or antineoplastic agent which exhibits poor or inconsistent oral bioavailability (e.g., paclitaxel, docetaxel or etoposide), comprises the oral co-administration to a mammalian patient of the target agent and an oral bioavailability-enhancing agent (e.g., cyclosporin A, cyclosporin D, cyclosporin F or ketoconazole). The enhancing agent may be administered orally from 0.5-24 hrs. prior to the oral administration of one or more doses of the target agent, substantially simultaneously with the target agent or both prior to and substantially simultaneously with the target agent.Type: ApplicationFiled: August 14, 2006Publication date: March 15, 2007Applicant: Teva North AmericaInventors: Samuel Broder, Kenneth Duchin, Sami Selim
-
Patent number: 7041640Abstract: A method of increasing the bioavailability upon oral administration of a pharmacologically active target agent, particularly an antitumor or antineoplastic agent which exhibits poor or inconsistent oral bioavailability (e.g., paclitaxel, docetaxel or etoposide), comprises the oral co-administration to a mammalian patient of the target agent and an oral bioavailability-enhancing agent (e.g., cyclosporin A, cyclosporin D, cyclosporin F or ketoconazole). The enhancing agent may be administered orally from 0.5-24 hrs. prior to the oral administration of one or more doses of the target agent, substantially simultaneously with the target agent or both prior to and substantially simultaneously with the target agent.Type: GrantFiled: March 15, 2004Date of Patent: May 9, 2006Assignee: Baker Norton Pharmaceuticals, Inc.Inventors: Samuel Broder, Kenneth L. Duchin, Sami Selim
-
Publication number: 20050238634Abstract: A method of increasing the bioavailability upon oral administration of a pharmacologically active target agent, particularly an antitumor or antineoplastic agent which exhibits poor or inconsistent oral bioavailability (e.g., paclitaxel, docetaxel or etoposide), comprises the oral co-administration to a mammalian patient of the target agent and an oral bioavailability-enhancing agent (e.g., cyclosporin A, cyclosporin D, cyclosporin F or ketoconazole). The enhancing agent may be administered orally from 0.5-24 hrs. prior to the oral administration of one or more doses of the target agent, substantially simultaneously with the target agent or both prior to and substantially simultaneously with the target agent.Type: ApplicationFiled: April 13, 2005Publication date: October 27, 2005Applicant: Baker Norton Pharmaceuticals, Inc.Inventors: Samuel Broder, Kenneth Duchin, Sami Selim
-
Patent number: 6936583Abstract: Taxane antineoplastic agents which have heretofore exhibited poor or non-existent oral bioavailability are administered orally to human patients suffering from taxane-responsive disease conditions and made sufficiently bioavailable to achieve therapeutic blood levels. In a preferred embodiment, the taxane, preferably paclitaxel, is co-administered to the patient with an oral cyclosporin enhancing agent, preferably cyclosporin A. By one preferred method, a dose of oral enhancer is administered about 0.5-72 hours before the taxane and a second dose of the enhancer and administered immediately before, together with or immediately after the taxane. A method of treating human patients suffering from taxane-responsive disease conditions is also provided, as well as a method for providing such treatment while preventing or reducing hypersensitivity and allergic reactions without the need for pre-medication.Type: GrantFiled: March 5, 2004Date of Patent: August 30, 2005Assignee: Baker Norton Pharmaceuticals, Inc.Inventors: Samuel Broder, Kenneth L. Duchin, Sami Selim
-
Patent number: 6818615Abstract: A method of increasing the bioavailability upon oral administration of a pharmacologically active target agent, particularly an antitumor or antineoplastic agent which exhibits poor or inconsistent oral bioavailability (e.g., paclitaxel, docetaxel or etoposide), comprises the oral co-administration to a mammalian patient of the target agent and an oral bioavailability-enhancing agent (e.g., cyclosporin A, cyclosporin D, cyclosporin F or ketoconazole). The enhancing agent may be administered orally from 0.5-24 hrs. prior to the oral administration of one or more doses of the target agent, substantially simultaneously with the target agent or both prior to and substantially simultaneously with the target agent.Type: GrantFiled: September 12, 2002Date of Patent: November 16, 2004Assignee: Baker Norton Pharmaceuticals, Inc.Inventors: Samuel Broder, Kenneth L. Duchin, Sami Selim
-
Publication number: 20040176439Abstract: A method of increasing the bioavailability upon oral administration of a pharmacologically active target agent, particularly an antitumor or antineoplastic agent which exhibits poor or inconsistent oral bioavailability (e.g., paclitaxel, docetaxel or etoposide), comprises the oral co-administration to a mammalian patient of the target agent and an oral bioavailability-enhancing agent (e.g., cyclosporin A, cyclosporin D, cyclosporin F or ketoconazole). The enhancing agent may be administered orally from 0.5-24 hrs. prior to the oral administration of one or more doses of the target agent, substantially simultaneously with the target agent or both prior to and substantially simultaneously with the target agent.Type: ApplicationFiled: March 15, 2004Publication date: September 9, 2004Applicant: Baker Norton Pharmaceuticals, Inc.Inventors: Samuel Broder, Kenneth L. Duchin, Sami Salim
-
Publication number: 20040171532Abstract: Taxane antineoplastic agents which have heretofore exhibited poor or non-existent oral bioavailability are administered orally to human patients suffering from taxane-responsive disease conditions and made sufficiently bioavailable to achieve therapeutic blood levels. In a preferred embodiment, the taxane, preferably paclitaxel, is co-administered to the patient with an oral cyclosporin enhancing agent, preferably cyclosporin A. By one preferred method, a dose of oral enhancer is administered about 0.5-72 hours before the taxane and a second dose of the enhancer and administered immediately before, together with or immediately after the taxane. A method of treating human patients suffering from taxane-responsive disease conditions is also provided, as well as a method for providing such treatment while preventing or reducing hypersensitivity and allergic reactions without the need for pre-medication.Type: ApplicationFiled: March 5, 2004Publication date: September 2, 2004Applicant: Baker Norton Pharmaceuticals, Inc.Inventors: Samuel Broder, Kenneth L. Duchin, Sami Selim
-
Patent number: 6730698Abstract: Taxane antineoplastic agents which have heretofore exhibited poor or non-existent oral bioavailability are administered orally to human patients suffering from taxane-responsive disease conditions and made sufficiently bioavailable to achieve therapeutic blood levels. In a preferred embodiment, the taxane, preferably paclitaxel, is co-administered to the patient with an oral cyclosporin enhancing agent, preferably cyclosporin A. By one preferred method, a dose of oral enhancer is administered about 0.5-72 hours before the taxane and a second dose of the enhancer and administered immediately before, together with or immediately after the taxane. A method of treating human patients suffering from taxane-responsive disease conditions is also provided, as well as a method for providing such treatment while preventing or reducing hypersensitivity and allergic reactions without the need for pre-medication.Type: GrantFiled: February 6, 2002Date of Patent: May 4, 2004Assignee: Baker Norton Pharmaceuticals, Inc.Inventors: Samuel Broder, Kenneth L. Duchin, Sami Selim
-
Patent number: 6610735Abstract: A method of increasing the bioavailability upon oral administration of a pharmacologically active target agent, particularly an antitumor or antineoplastic agent which exhibits poor or inconsistent oral bioavailability (e.g., paclitaxel, docetaxel or etoposide), comprises the oral co-administration to a mammalian patient of the target agent and an oral bioavailability-enhancing agent (e.g., cyclosporin A, cyclosporin D, cyclosporin F or ketoconazole). The enhancing agent may be administered orally from 0.5-24 hrs. prior to the oral administration of one or more doses of the target agent, substantially simultaneously with the target agent or both prior to and substantially simultaneously with the target agent.Type: GrantFiled: April 10, 2001Date of Patent: August 26, 2003Assignee: Baker Norton Pharmaceuticals, Inc.Inventors: Samuel Broder, Kenneth L. Duchin, Sami Selim
-
Publication number: 20030069301Abstract: A method of increasing the bioavailability upon oral administration of a pharmacologically active target agent, particularly an antitumor or antineoplastic agent which exhibits poor or inconsistent oral bioavailability (e.g., paclitaxel, docetaxel or etoposide), comprises the oral co-administration to a mammalian patient of the target agent and an oral bioavailability-enhancing agent (e.g., cyclosporin A, cyclosporin D, cyclosporin F or ketoconazole). The enhancing agent may be administered orally from 0.5-24 hrs. prior to the oral administration of one or more doses of the target agent, substantially simultaneously with the target agent or both prior to and substantially simultaneously with the target agent.Type: ApplicationFiled: September 12, 2002Publication date: April 10, 2003Applicant: Baker Norton Pharmaceuticals, Inc.Inventors: Samuel Broder, Kenneth L. Duchin, Sami Selim
-
Publication number: 20020156125Abstract: Taxane antineoplastic agents which have heretofore exhibited poor or non-existent oral bioavailability are administered orally to human patients suffering from taxane-responsive disease conditions and made sufficiently bioavailable to achieve therapeutic blood levels. In a preferred embodiment, the taxane, preferably paclitaxel, is co-administered to the patient with an oral cyclosporin enhancing agent, preferably cyclosporin A. By one preferred method, a dose of oral enhancer is administered about 0.5-72 hours before the taxane and a second dose of the enhancer and administered immediately before, together with or immediately after the taxane. A method of treating human patients suffering from taxane-responsive disease conditions is also provided, as well as a method for providing such treatment while preventing or reducing hypersensitivity and allergic reactions without the need for pre-medication.Type: ApplicationFiled: February 6, 2002Publication date: October 24, 2002Inventors: Samuel Broder, Kenneth L. Duchin, Sami Selim
-
Patent number: 6395770Abstract: Taxane antineoplastic agents which have heretofore exhibited poor or non-existent oral bioavailability are administered orally to human patients suffering from taxane-responsive disease conditions and made sufficiently bioavailable to achieve therapeutic blood levels. In a preferred embodiment, the taxane, preferably paclitaxel, is co-administered to the patient with an oral cyclosporin enhancing agent, preferably cyclosporin A. By one preferred method, a dose of oral enhancer is administered about 0.5-72 hours before the taxane and a second dose of the enhancer and administered immediately before, together with or immediately after the taxane. A method of treating human patients suffering from taxaneresponsive disease conditions is also provided, as well as a method for providing such treatment while preventing or reducing hypersensitivity and allergic reactions without the need for pre-medication.Type: GrantFiled: August 28, 1999Date of Patent: May 28, 2002Assignee: Baker Norton Pharmaceuticals, Inc.Inventors: Samuel Broder, Kenneth L. Duchin, Sami Selim
-
Publication number: 20020058616Abstract: A method of increasing the bioavailability upon oral administration of a pharmacologically active target agent, particularly an antitumor or antineoplastic agent which exhibits poor or inconsistent oral bioavailability (e.g., paclitaxel, docetaxel or etoposide), comprises the oral co-administration to a mammalian patient of the target agent and an oral bioavailability-enhancing agent (e.g., cyclosporin A, cyclosporin D, cyclosporin F or ketoconazole). The enhancing agent may be administered orally from 0.5-24 hrs. prior to the oral administration of one or more doses of the target agent, substantially simultaneously with the target agent or both prior to and substantially simultaneously with the target agent.Type: ApplicationFiled: April 10, 2001Publication date: May 16, 2002Inventors: Samuel Broder, Kenneth L. Duchin, Sami Selim
-
Patent number: 6284800Abstract: The present invention comprises methods and compositions for the treatment of bronchorestrictive disorders, including asthma, in humans or animals. The methods and compositions are effective in treatment of inflammatory responses, such as those found in asthma and other related pathologies.Type: GrantFiled: March 13, 1998Date of Patent: September 4, 2001Assignee: Baker Norton Pharmaceuticals, Inc.Inventors: Samuel Broder, Tahir Ahmed
-
Patent number: 6245805Abstract: A method of increasing the bioavailability upon oral administration of a pharmacologically active target agent, particularly an antitumor or antineoplastic agent which exhibits poor or inconsistent oral bioavailability (e.g., paclitaxel, docetaxel or etoposide), comprises the oral co-administration to a mammalian patient of the target agent and an oral bioavailability-enhancing agent (e.g., cyclosporin A, cyclosporin D, cyclosporin F or ketoconazole). The enhancing agent may be administered orally from 0.5-24 hrs. prior to the oral administration of one or more doses of the target agent, substantially simultaneously with the target agent or both prior to and substantially simultaneously with the target agent.Type: GrantFiled: October 16, 1996Date of Patent: June 12, 2001Assignee: Baker Norton Pharmaceuticals, Inc.Inventors: Samuel Broder, Kenneth L. Duchin, Sami Selim
-
Patent number: 5968972Abstract: A method of increasing the bioavailability upon oral administration of a pharmacologically active target agent, particularly an antitumor or antineoplastic agent which exhibits poor or inconsistent oral bioavailability (e.g., paclitaxel or etoposide), comprises the oral co-administration to a mammalian patient of the target agent and an oral bioavailability-enhancing agent, (e.g., cyclosporin A, cyclosporin D, ketoconazole or captopril). The enhancing agent may be administered orally from 0.5-24 hrs. prior to the oral administration of one or more doses of the target agent, substantially simultaneously with the target agent or both prior to and substantially simultaneously with the target agent.Type: GrantFiled: February 29, 1996Date of Patent: October 19, 1999Assignee: Baker Norton Pharmaceuticals, Inc.Inventors: Samuel Broder, Kenneth L. Duchin, Sami Selim
-
Patent number: 5690910Abstract: A method of treating a patient suffering from antigen-induced asthma who has been challenged with an antigen, or providing chronic treatment to an asthma patient to reduce airway hyperresponsiveness, comprising intrabronchial administration to the patient of a pharmaceutical composition containing in each dose about 0.05 to about 1.0 mg of ultra-low molecular weight heparins (ULMWH), having an average molecular weight of 3,000 daltons or less, per kilogram of patient body weight, Inhalant pharmaceutical compositions for use in the novel treatment method are also provided.Type: GrantFiled: August 18, 1995Date of Patent: November 25, 1997Assignee: Baker Norton Pharmaceuticals, Inc.Inventors: Tahir Ahmed, Samuel Broder, John K. Whisnant
-
Patent number: 5616566Abstract: A method for inhibiting intracellular replication of HIV in an HIV-infected individual comprising contacting the HIV reverse transcriptase in the HIV-infected cells with 2',3'-dideoxyadenosine-5'-triphosphate whose source is 2',3'-dideoxyadenosine or a pharmaceutically acceptable salt or prodrug thereof.Type: GrantFiled: April 30, 1993Date of Patent: April 1, 1997Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Hiroaki Mitsuya, Samuel Broder, Robert Yarchoan